Hemostemix Inc · TSXV:HEM
Hemostemix — Investor Presentation (April 2023)
24 slides from Hemostemix's investor presentation, April 2023
Slide 1: Autologous Stem Cell Therapeutics
AUTOLOGOUS STEM CELL THERAPEUTICS Q1 PRESENTATION F Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) © Hemostemix Inc. All Rights Reserved.
Slide 2: Forward-Looking Information
Forward-Looking Information This presentation contains forward looking statements that reflect management’s Actual results, performance and achievement(s) could differ materially from that expectations regarding the future growth and results of operational performance expressed in, or implied by, an
Slide 3: Hemostemix Vision
Global Business Opportunity Hemostemix Vision Hemostemix Vision is to be the first, Compassionate Treatments: 93.5% of most affordable, autologous stem cell ACP-01 treated Limbs were saved from therapy company approved to treat Amputation In Phase II trial. critical limb ischemia and ischemic cardio
Slide 4: Market Size
Market Size Ischemic Cardiomyopathy $5.7 Billion by 2028 Source: Transparency Research Critical Limb Ischemia (CLI) $3.49 Billion by 2031 Source: Transparency Research 4
Slide 5: The Hemostemix Platform
The Hemostemix Platform ACP NCP- CCP- -01 01 01 Angiogenic Cell Precursor Neuronal Cell Precursor Cardiomyocyte Cell Precursor Neovascularization at the site of Rebuilds neuronal pathways Rebuilds Heart following Infarct ischemia Homes to site of injury Proposed to Mate with bioscaffold to CLI & PAD
Slide 6: Synergetic Cell Population Becomes ACP-01
Synergetic Cell Population Becomes ACP-01 Multipotent Cells Enrichment Low Density Cells Confidential
Slide 7: Viability & Mechanism of Action
Viability & Mechanism of Action % Parameters Recovery Total Cells number 79 Viability 100 % CD34 positive cells 86 ACPs number 86 IL-8 Secretion 96 35 Hours Shelf Life in 98 Syringe
Slide 8: ACP-01 Clinical Trial History
ACP-01 Clinical Trial History Clinical Trial Pilot Safety/ Phase 1b Safety Phase 2 Safety Safety and Safety and Type of Study Safety and Feasibility and Efficacy and Efficacy Efficacy Efficacy Feasibility Canada and Bangkok Heart Study Location Thailand Hungary Thailand Thailand United States Hospit
Slide 9: Retrospective ACP-01 Cardiomyopathy Study Results
Retrospective ACP-01 Cardiomyopathy Study Results 53 consecutive patients who underwent transcatheter intramyocardial or intracoronary injection of ACP-01 for the treatment of cardiomyopathy were studied. The pre and post-procedure ejection fraction percentage (EF%), were reported from MUGA scan, SP
Slide 10: Cardiomyopathy Study Highlights
Cardiomyopathy The non-ischemic dilated cardiomyopathy patients (n=8), Study Highlights IMPROVED +14.35% improved from 25.94% before treatment to 40.29% at final follow- up, for an overall improvement of 14.35% (p<0.002) at 12 months. IMPROVED For ischemic heart failure alone +8.37% (n=41), LVEF inc
Slide 11: Changes in LVEF
Changes in LVEF Change in LVEF 60 50 40 Pretx n=53 Important Average LVEF 30 Posttx n=52, Overall, upward mobility from one quartile p=0.0007 to the next quartile was significant 20 (p=.0007) for first follow up, and more Final n=35, p=0.0002 significant (p=0.0002) for final follow up. 10 Three of t
Slide 12: Changes in CLI Mean Wound Area by Visit 7
Changes in CLI Mean Wound Area by Visit 7 ACP-01 Placebo Important By visit 7, the mean wound area of the ACP-01 cohort decreased 5.45 mm3 from 6.2 mm3 to 0.749 mm3 while the mean wound area of the Placebo treated group, by Visit 7, decreased approximately 1 mm3 from 5 mm3 to 4 mm3. 12
Slide 13: ACP-01 7-Day, Scalable Process
ACP-01 7-Day, Scalable Process 1 2 3 4 5 6 7 B lood collection Isolation of Culturing and Cell Q uality Control Packaging Administration and shipping SCP d ifferentiation harvesting release tests and shippin g of cells to of cells and batch damaged qualification tissue 13
Slide 14: Key Differentiators of ACP-01
Key Differentiators of ACP-01 Non-surgical, enhanced cell therapy Simple, cost-effective treatment for restoring circulation to blood production process starved tissues and organs Scalable Low No Patient Ethical Self-donation, means Risks Concerns Stem cells derived no immune rejection or Ready in d
Slide 15: Unique Properties
Unique Properties Non-surgical, enhanced cell therapy treatment for restoring circulation to blood starved tissues and organs Patented peripheral Created from the ACP-01 are cultured in Sourced, Five patent families, blood-based patients own blood, the patients’ serum, processed and including compos
Slide 16: Scalable Production
Scalable Production A Stepped Approach to Automated Scaled Production and Profitability STEP 1 STEP 2 STEP 3 STEP 4 STEP 5 STEP 6 MANUAL SEMI-AUTO F U L LY AU TO M AT E D 20 batches/mo. 40 batches/mo. 60 batches/mo. 72 batches/mo. 80 batches/mo. 4000 batches/mo. l Team 2 Teams 2 Teams 2 Teams 2 Team
Slide 17: Milestones and Scalability
Milestones and Scalability Refractory Angina Non-Risk Adjusted * Ischemic Cardiomyopathy Congestive Heart Risk Adjusted Failure Peripheral Arterial Disease SAM (Current) x 100 * Based on 0.5% North American, European Union Addressable Market. Non- Risk Adjusted Subject to Phase 1: Phase 2: Phase 3 P
Slide 18: Business Advisory Board
Business Advisory Board HONORABLE SHELIA COPPS DAVID H. TSUBOUCHI OC, PC B.A., J.D., LL.D., D.S.Litt., C.Dir. Former Deputy Prime Minister of First Japanese Canadian to be Canada, Minister of Environment, elected to any provincial legislature Minister of Heritage and a senior in Canada and to be app
Slide 19: Management & Board of Directors
Management & Board of Directors DR. INA PETE PAVLIN THOMAS DR. FRASER SAREL P.Eng., SMEENK HENDERSON Vice President BA President & PhD, Chief MD, Chief Operations CEO, Co-Founder Scientific Officer Medical Officer & Director DR. RONNIE PETER LACEY LORAN HERSHMAN ICD.D Chairman SWANBERG M.D., F.C.C.S
Slide 20: Scientific Advisory Board Additions
Scientific Advisory Board Additions DR. NADIA GIANNETTI DR. TERRY HEBERT DR. RENZO CECERE Associate Chief of Medicine Assistant Dean, Director Chief, Division Cardiac Chief of Cardiology McGill Regenerative Surgery, McGill University McGill University Medicine DR. JOHANNES GRILLARI DR. ERNST VON SCH
Slide 21: Takeaways
No signs of toxicity or rejection with ACP 01 autologous Over 500 stem cells patients treated with Highly ACP 01 scalable Safely with Statistical Efficacy Takeaways Multiple Little if any indications competing equates to products – multi-billion Hemostemix plus in a class by opportunity Up to itself
Slide 22: Contact
THOMAS SMEENK President, CEO, Co-Founder Contact [email protected] +1-905-580-4170 22
Slide 23: Appendix A
Appendix A Dr. Fraser Henderson Sr., CMO Dr. Fraser Henderson is an exceptional neurological surgeon with extensive experience and expertise in all facets of neurosurgery and neurological science. Dr. Henderson is Director of The Metropolitan Neurosurgery Group, LLC, Chief of Neurosurgery at Luminis
Slide 24: Appendix A
Appendix A Dr. Ina Sarel, CSO • Over 25 years of stem cell therapy discovery and business experience • Mother of Neural Cell Precursors • VP Product Development, Cellect Biotechnology Oct 2017 - Dec 2019 • Vice President R&D, Hemostemix 2011 - Oct 2017 • Director of R&D, Hemostemix 2008 – 2010 • Dir